Over the last four decades, molecular cloning has evolved tremendously. Efficient products allowing assembly of multiple DNA fragments have become available. However, cost-effective tools for engineering antibodies of different specificities, isotypes and species are still needed for many research and clinical applications in academia. Here, we report a method for one-step assembly of antibody heavy-and light-chain DNAs into a single mammalian expression vector, starting from DNAs encoding the desired variable and constant regions, which allows antibodies of different isotypes and specificity to be rapidly generated. As a proof of principle we have cloned, expressed and characterized functional recombinant tumor-associated antigen-specific chimeric IgE/k and IgG 1 /k, as well as recombinant grass pollen allergen Phl p 7 specific fully human IgE/l and IgG 4 /l antibodies. This method utilizing the antibody expression vectors, available at Addgene, has many applications, including the potential to support simultaneous processing of antibody panels, to facilitate mechanistic studies of antigen-antibody interactions and to conduct early evaluations of antibody functions.
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I
n the last 30 years, antibody-based immunotherapies have been applied to treat a variety of diseases 1 and there is a constant development of novel antibodies [2] [3] [4] . This has required the selection of recombinant monoclonal antibodies (mAbs) with high affinity for the appropriate epitopes on the target antigen and other desirable characteristics, such as the antibody isotype and effector functions. Large cDNA libraries of the variable (V) gene segments of antibodies are frequently generated in the study of immune disorders that involve B-cells, such as autoimmune diseases 5 , allergy and asthma [6] [7] [8] [9] [10] [11] [12] or cancer [13] [14] [15] [16] [17] . While this provides an insight at the genetic level, the antigen binding and effector functions may only be elucidated from the expressed antibody. Similarly, large libraries of scFv may be generated using phage display experiments and screened to identify antigen specificity 18 , and would benefit from a method of rapid reformatting as full-length antibodies, in order to evaluate their biological function.
Conventional methods for recombinant expression of whole antibodies of interest typically require the establishment of cell lines derived from CHO, mouse myeloma, or PER.C6 cells [19] [20] [21] [22] [23] [24] . This tends to be a lengthy, low efficiency process involving extensive selection and screening and is consequently unfavourable for expressing large numbers of antibodies for functional studies, as may be required after generating a variable gene library.
Matched Ig heavy-and light-chain V-regions of desired specificity have been amplified from single B cellderived cDNA and linked to the desired Ig constant (C) region in separate vectors encoding either the heavy-or light-chain DNA. Transient transfection of these vectors in mammalian HEK293 cells has enabled the rapid production of recombinant mAbs 12, [25] [26] [27] [28] . Although these facilitate expression of a large number of mAbs in a short time, in our experience, the transient co-transfection of separate vectors doubles the DNA preparation work, requires maxi or mega plasmid purifications and large amount of transfection reagent for the production of milligrams of antibody, which is a costly, labor-and time-intensive scale-up process. This limitation has been addressed by the generation of vectors hosting a dual antibody expression cassette with a selection marker [29] [30] [31] . However, all these antibody cloning systems rely on restriction enzyme-and ligation-dependent cloning methods, which adds an additional cost, prevents high-throughput analysis of antibody candidates, and may sometimes be impractical due to the lack of compatible restriction sites.
A suitable high-throughput antibody cloning method would enable reliable assembly of antibody heavy and light chains in a single vector via a cheap, rapid, and convenient platform. An alternative to the conventional cloning methods, the Polymerase Incomplete Primer Extension (PIPE) method, has been shown to be highly efficient, cost-effective and capable of supporting the high-throughput cloning of thousands of genes in parallel in a short period of time 32 . Therefore, utilizing the PIPE cloning method, we sought to develop an improved flexible system for cloning of antibodies of any isotype and specificity. We aimed to minimize the cost and time required to clone antibody heavy and light chains into a single mammalian expression vector for stable transfection of a suitable cell line, allowing an easily scalable production process and delivering sufficient material for pre-clinical studies.
In this study we describe an efficient and cost-effective method for antibody cloning that facilitated the seamless exchange of antibody variable and constant domains to produce fully functional recombinant antibodies. As a proof-of-principle, we engineered tumorassociated antigen chondroitin sulfate proteoglycan 4 (CSPG4) specific chimeric IgE/k and IgG 1 /k and grass pollen allergen Phl p 7 specific human IgE/l and IgG 4 /l antibody isotypes. The choice of these antibodies was dictated by the search for antibodies with potential applications for the diagnosis or immunotherapy of melanoma and allergy, respectively.
Results
Antibody Cloning by PIPE. We adopted the PIPE cloning method for construction of antibody expression vectors and swapping of variable/constant regions. The antibody cloning method represents a simple two-step protocol with complete design flexibility ( Figure 1 ). In the first step, a pair of 40 bp vector-specific primers is used for PCR vector linearization and generation of singlestranded 59-ends by PIPE (Figure 1, Step 1a) . Simultaneously, another pair of 40 bp primers with 59-vector-end overlapping sequences is used for insert PCR amplification, generating singlestranded vector-end homologous products by PIPE (Figure 1, Step 1b). In the second step, the unpurified PIPE products are mixed and the single-stranded overlapping sequences anneal and assemble as a complete vector ( Figure 1, Step 2).
Following the steps outlined in Figure 1 , we designed the construction of a dual antibody expression cassette into pVITRO1 mammalian expression vector (see Supplementary Fig. S1 online). PCR linearization of pVITRO1 at Multiple Cloning Site 2 (MCS2) allowed the insertion of a heavy chain expression cassette under the action of a SV40 enhancer. In a subsequent PIPE cloning reaction, a sequence verified clone pVITRO1-IgE (containing the human Epsilon heavy chain expression cassette at MCS2) was used as a template for PCR vector linearization at MCS1. This allowed the insertion of a human light chain (Lambda or Kappa) expression cassette under the action of a human CMV enhancer. Transformants were sequenced across the annealing junctions to confirm that the dual antibody expression vectors pVITRO1-IgE/l and pVITRO1-IgE/k were successfully assembled (see Supplementary Fig. S1 online) .
Having successfully utilised the PIPE cloning method for vector construction we aimed to swap antibody variable regions. This process involved exchanging existing V H and V K regions in pVITRO1-IgE/k, without affecting the Ce and Ck. To achieve this, four primer pairs were designed. The first two vector-specific primer pairs, flanking the existing V H and V K , were used for amplification of two vector fragments, subsequently treated by DpnI to destroy the E. coliderived PCR template (Figure 2) .
Agarose gel electrophoresis analysis of the PCR amplified vector fragments showed clear DNA products with no unspecific amplifications (see Supplementary Fig. S2 online) and sequencing identified no mutations. The second two primer pairs, with 59-vector-fragment-end overlapping sequences, were used for amplification of the incoming CSPG4-specific V H and V K (see Supplementary  Figure S2 online). The four unpurified PCR products were simply mixed together (v/v) and transformed into chemically competent E. coli cells (NEB 10-beta). DNA sequencing of a single colony confirmed the correct annealing of the vector fragments with the CSPG4-specific V H and V K , assembling a complete pVITRO1-CSPG4-IgE/k vector, coding for the expression of chimeric anti-CSPG4 IgE antibody (Figure 2 ). Similarly, a pVITRO1-102.1F10-IgE/l vector coding for the expression of anti-Phl p 7 IgE was generated, demonstrating the system's simplicity to exchange variable-region domains within the same antibody isotype. Furthermore, a high-throughput antibody cloning method requires a minimum number of colonies to be picked and tested for correct assembly. Therefore, the efficiency of the PIPE cloning method to swap variable regions was compared against the Gibson Assembly (NEB) and GeneArtH Seamless Cloning (Life Technologies) kits, following the manufacturer's instructions to represent optimized conditions for these methods. Sequencing of plasmids, purified from single colonies, over the annealing junctions showed comparable number of colonies with correctly assembled vectors by PIPE and the two commercially available kits (see Supplementary Table S1 online). In the PIPE cloning reaction, 90% of the sequenced colonies represented the correct clone, compared with 88.5% for GeneArtH Seamless Cloning and 91.3% for Gibson Assembly. The rest of the colonies represented the original PCR vector template. Colonies with incorrectly assembled DNA fragments were not identified using any of the three cloning methods.
The PIPE cloning method was also applied for swapping heavy chain constant regions within the dual antibody expression vectors. We aimed to exchange the existing Ce region within the pVITRO1-CSPG4-IgE/k vector without affecting C K and CSPG4-specific V H and V K . Using a vector-specific primer pair flanking the existing Ce region, the vector was linearized and subsequently DpnI-treated to destroy the E. coli-derived PCR template. Agarose gel electrophoresis analysis of the PCR linearized vector showed no unspecific amplifications (see Supplementary Figure S2 online) and sequencing identified no mutations. A second primer pair with 59-vector-end overlapping sequences was used for amplification of the incoming Cc 1 (see Supplementary Fig. S2 online) . The unpurified DpnI-treated linearized vector and Cc 1 PCR products were mixed together (v/v) and transformed into competent E. coli cells (NEB 10-beta). DNA sequencing of a single colony confirmed the correct assembly of a complete pVITRO1-CSPG4-IgG 1 /k vector, coding for the expression of chimeric anti-CSPG4 IgG 1 antibody (see Supplementary Fig.  S3 online) . Similarly, vectors coding for the expression of Phl p 7 allergen specific fully human IgG 1 , IgG 2 , IgG 3 , IgG 4 , IgA 1 and IgA 2 isotypes were generated, demonstrating the system's simplicity to exchange constant-region antibody domains allowing cloning of different antibody isotypes with the same specificity. Furthermore, to investigate the frequency of mutations in the vectors generated by PIPE cloning, we have sequenced the entire vectors. Sequencing results confirmed no mutations were present in the vectors after swapping variable or constant regions.
The overall time required for swapping variable or constant regions within the antibody expression vectors took just a few hours and the individual steps are outlined in Table 1 . It is important to mention that any competent E. coli cells can be used for the PIPE antibody cloning; however the use of highly competent cells increases the cloning efficiency. Incubating the cloning mixtures for 1 hour at room temperature or overnight at 16uC also improves cloning efficiency.
Recombinant Antibody Production. Having successfully adapted and optimized the PIPE cloning method for exchange of variable-or constant-region domains within the dual antibody expression cassette in pVITRO1, we aimed to develop a large-scale antibody Antibody Characterization. Purity and apparent molecular weight of purified antibodies was assessed by SDS-PAGE analysis. Under non-reducing conditions, apparent molecular sizes were found to be between 180-250 kDa for the heterotetrameric IgG 1 /IgG 4 antibodies and 250 kDa for the heterotetrameric IgE antibody (Figure 4a,c) . Under reducing conditions, protein bands corresponding to the heavy (52-72 kDa) and light chains were identified (Figure 4b,d) . Free light or heavy chain was not detected, suggesting that the antibody chains are assembled into whole antibody molecules. The molecular sizes corresponding to the heavy and light chains suggest the secreted antibodies are properly folded and glycosylated 29, 30 . Similar results were obtained when assessing the IgG 2 , IgG 3 , IgA 1 and IgA 2 isotypes under reducing conditions, with protein bands corresponding to the heavy chains (50-60 kDa) and light chains at 25 kDa ( Figure 5 ).
Size-exclusion chromatography was used for biophysical analysis of the purified anti-CSPG4 IgE/IgG 1 , 102.1F10 IgE/IgG 4 and isotype controls, as described previously 33 . MOv18 IgE/IgG 1 , antibodies directed against the ovarian cancer antigen folate receptor alpha 34 and a commercially available human myeloma IgG 4 (Millipore), respectively, were used as isotype controls. The size-exclusion chromatography analysis showed no aggregation and confirmed the purified products consisted of monodisperse antibodies (Figure 4e-g ).
Antibody Functionality. The functional characteristics of recombinantly expressed and purified antibodies were assessed by flow cytometric analysis. Both anti-CSPG4 IgE and IgG 1 antibodies bound to CSPG4
1 A375 human melanoma cells, but not to CSPG4 2 primary human melanocytes (Figure 6a ). The Fc receptorbinding activities of the antibodies were analysed using the human monocytic cell line U937, which expresses Fcc receptors at medium densities, or to RBL SX38 rat basophilic leukaemia cells, which express both human and rat high affinity IgE receptor FceRI Binding of anti-CSPG4 IgE and IgG 1 antibodies to the surface of the A375 tumour cells was also confirmed by immunofluorescence microscopy, while hapten specific isotype control, NIP-IgE and IgG 1 antibodies did not show binding above background levels (Figure 6c ). Therefore, both flow cytometric and immunofluorescence analyses of anti-CSPG4 IgE and IgG 1 confirmed that the antibodies recognized and bound their expected tumour targetexpressing cells specifically.
Allergen specificity of 102.1F10 IgE/IgG 4 antibodies was confirmed by means of a sandwich ELISA. The Phl p 7-specific antibodies bound to the allergen coated onto plates at levels comparable to those measured with serum from a patient diagnosed with grass pollen allergy, while the isotype controls showed no binding above background levels (Figure 6d ).
Discussion
Over the last three decades, recombinant mAbs have become a key tool for basic research, diagnosis and treatment of human diseases. The increasing demand for therapeutic antibodies has resulted in a significant improvement in antibody production systems, allowing biopharmaceutical communities to reach grams per liter expression levels. However, new efficient and cost-effective cloning and expression platforms ensuring consistent antibody production are highly desirable to facilitate research using recombinant antibodies in academic settings.
An ideal antibody cloning method would require the minimum costs of labor and reagents and deliver high success rate of correctly assembled expression vectors. Conventional methods for antibody cloning utilize restriction enzymes, ligases and DNA purification kits, which is a labor-intensive procedure introducing additional costs. The exponential growth in the field of molecular cloning in recent years has yielded to the development and availability of efficient and time-effective cloning products such as Gibson Assembly (NEB), GeneArtH Seamless Cloning (Life Technologies) and GatewayH Cloning (Invitrogen). Although these products allow the assembly of multiple DNA fragments in just a few hours, they add an additional cost to the antibody cloning procedure. To overcome this limitation, we have used the Polymerase Incomplete Primer Extension (PIPE) method 32 to construct a dual antibody expression cassette in the pVITRO1 mammalian expression vector. The PIPE method relies on the inefficiency of the amplification process in the final cycles of a PCR reaction, possibly due to the decreasing availability of dNTPs. This incomplete 59-39 primer extension results in a mixture of PCR products with variably single-stranded 59-ends 36 . These can be used as annealing junctions for PCR products sharing homologous single-stranded 59-ends, and nicks and gaps are repaired in vivo after transformation 32 . In our experiments, antibody cloning by PIPE delivered similar success rate of correctly assembled vectors compared to the commercially available cloning kits (see Supplementary Table S1 online). Adopting the PIPE cloning technique, combined with a single vector system, which simultaneously accommodates antibody heavy and light chains, we developed an efficient and cost-effective method for antibody cloning and production based on previously established disparate technologies.
Here, cloning the heavy and light antibody chains is conducted in just a few hours, and in principle, this could be applied for the generation of expression vectors of antibodies of any species (see Supplementary Table S2 online) and isotype with any desired specificity, given the availability of DNAs encoding the heavy-and light-chain V and C regions. When combined with the downstream transfection of pVITRO1 expression vectors into Human Embryonic Kidney (HEK) 293-F cells, followed by hygromycin B selection, this strategy can yield reproducible generation of tens of milligram quantities of functional recombinant mAb in less than four weeks from cloning of the V-and C-region DNA, through to harvesting of selected cell supernatants. Recombinant mAbs have been produced in HEK 293-F cells [25] [26] [27] 37, 38 and although cloning the dual antibody cassette into pVITRO1 for expression in these cells has facilitated appreciable expression yields (Figure 3) , the cassette can be transferred to any compatible expression vector consisting of two transcription units for use in alternative systems, if required.
Using this method, we have generated vectors coding for the expression of antibodies of different isotypes directed against two different antigens (CSPG4, Phl p 7). In principle, the method could be advantageous for the functional analysis of V gene libraries derived from isolated mRNA from single B cells or by phage display, since an extensive panel of recombinant antibodies may be generated in a relatively short period of time. Additionally, C-region exchange to generate antibodies of different isotypes could enable the direct comparison of different antibody effector functions and also of interspecies differences. Here we have produced fully human IgG 1 , IgG 2 , IgG 3 , IgG 4 , IgE, IgA 1 and IgA 2 isotypes ( Figure 5 ) with the same specificity to allergen Phl p 7 and in the field of allergen immunotherapy it may be desirable to compare the properties of different antibody isotypes in order to select the most efficacious antibody treatment. In another example, different isotypes specific for the tumor-associated antigen CSPG4 can be produced to elucidate their potential antitumor effects against solid cancers.
In summary, we report a platform entailing antibody cloning in a single mammalian expression vector and scalable production process that can deliver appreciable protein yields to facilitate a variety of pre-clinical studies and future clinical applications.
Methods
Construction of Dual Antibody Expression Vectors by PIPE. pVITRO1 (InvivoGen) vector-specific oligonucleotides (desalted, Sigma) MCS2_F and MCS2_R (Table 2) were used for PCR vector linearization at multiple cloning site 2 (MCS2). A PCR reaction was set up containing 0.5 mM each of these primers, 25 ml 23 Phusion TM Flash High-Fidelity PCR Master Mix (Finnzymes), 10 ng of pVITRO1 vector template and MilliQ water to 50 ml. The reaction was treated as follows: initial denaturation for 30 seconds at 98uC, then 30 cycles of denaturation for 10 seconds at 98uC, annealing for 15 seconds at 60uC and extension for 1 minute 50 seconds at 72uC, followed by a cool down to 4uC. The linearized vector was subsequently treated with DpnI (New England Biolabs) according to the manufacturer's instructions. In parallel, a human e heavy chain expression cassette (V H 1-02 secretary leader, V H and Ce) was amplified from a monocistronic vector pIge 39 using primers HC_F and HC_R (Table 2) , which included 59-ends complementary to the MCS2 of pVITRO1 and 39-ends complementary to the V H 1-02 secretary leader and Ce terminus respectively. The heavy chain PCR reaction was treated exactly as above, except the extension step was reduced to 20 seconds at 72uC. Unpurified PCR products were mixed 151 (v/v) and 2 ml of the mixture were transformed into chemically competent E. coli cells (High Efficiency NEB 10-beta). Transformation was performed according to the manufacturer's instructions, except the culture was not diluted in SOC media after incubation at 37uC and 200 ml were plated onto Fast-MediaH Hygro Agar LB petri dishes (InvivoGen). In a subsequent PIPE cloning reaction, a sequence verified clone pVITRO1-IgE (contacting e heavy chain expression cassette at MCS2) was PCR linearized at MCS1 by vector-specific primers MCS1_F and MCS1_R (Table 2 ) with extension step for 2 minutes at 72uC, followed by a DpnI treatment. A human kappa light chain expression cassette (VkA26 secretary leader, Vk and Ck) was amplified from a monocistronic vector pIgk 39 using primers KC_F and KC_R (Table 2) , in which the 59-ends are complementary to the MCS1 of pVITRO1 and 39-ends complementary to the VkA26 secretary leader and Ck terminus respectively. Similarly, a human lambda light chain expression cassette (Vl 8a secretary leader, Vl and Cl) was amplified from a monocistronic pIgl vector 12 using primers LC_F and LC_R (Table 2) . Light chain PCR reactions included an extension step for 10 seconds at 72uC. Unpurified DpnI-treated linearized vector was mixed 151 (v/v) with unpurified kappa or lambda light chain PCR product and 2 ml of the mixture were transformed into competent E. coli cells as described above.
Swapping Antibody Variable Regions by PIPE. The dual antibody expression vectors were used to swap antibody variable regions by PIPE cloning. pVITRO1-IgE/ kvector was linearized by two sets of vector-specific primer pairs flanking the existent V K and V H ; Linear_Kfwd with Linear_Hrev and Linear_Hfwd with Linear_Krev (Table 2 ), in two independent PCR reactions. The PCR reactions were treated exactly as above, except the extension step was carried out for 55 seconds at 72uC, followed by a DpnI treatment of the two resulting PCR vector fragment products. Simultaneously, CSPG4-specific V H and V K were PCR amplified from previously cloned monocistronic pIge-CSPG4 and pIgk-CSPG4 vectors, bearing previously published CSPG4 specific variable regions 40 . Two sets of primer pairs; CSPG4H_Fwd with CSPG4H_Rev and CSPG4K_Fwd with CSPG4K_Rev (Table 2) , were used in two independent PCR reactions with extension step for 5 seconds at 72uC. In the first primer pair CSPG4H_Fwd and CSPG4H_Rev, the 59-ends are complementary to the V H 1-02 secretary leader terminus and start of Ce respectively, while 39-ends are CSPG4-V H specific. In the second primer pair CSPG4K_Fwd and CSPG4K_Rev, the 59-ends are complementary to the Vk A26 secretary leader terminus and start of Ck respectively, while 39-ends are CSPG4-V K specific. The DpnI-treated unpurified vector fragments were mixed with the unpurified CSPG4 specific V H and V K in 1515151 (v/v) ratio and 2 ml from the mixture transformed into competent E. coli cells as described above, assembling a pVITRO1-CSPG4-IgE/k vector. Similarly, pVITRO1-IgE/l vector was linearized by two sets of vector-specific primer pairs; Linear_Lfwd with Linear_Hrev and Linear_Hfwd with Linear_Lrev (Table 2) , and Phl p 7 specific (102.1F10) V H and V K were PCR amplified from monocistronic vectors 12 by two sets of primer pairs; 102.1F10H_Fwd with 102.1F10H_Rev and 102.1F10L_Fwd with 102.1F10L_Rev, for the assembling reaction of the pVITRO1-102.1F10-IgE/l vector.
To compare the cloning efficiency between different DNA assembly methods, vector pVITRO1-CSPG4-IgE/k was cloned by PIPE, Gibson Assembly (New England Biolabs) and GeneArtH Seamless Cloning (Life Technologies) method. The two vector fragments, amplified from pVITRO1-IgE/k vector template, were mixed with vector fragment terminal end-homologous CSPG4 specific V H and V K in a PIPE cloning reaction as previously described, while Gibson Assembly and GeneArtH Seamless Cloning kits were used according to the manufacturer's specifications.
Swapping Antibody Constant Regions by PIPE. The PIPE cloning method was also used to swap constant regions within the dual antibody expression vectors. pVITRO1-CSPG4-IgE/k vector was linearized by primer pair pAn_Fwd and CSPG4-VH_Rev (Table 2) , flanking the Ce region. The PCR reaction was treated exactly as above, except the extension step for 2 minutes at 72uC, followed by DpnI treatment. Simultaneously, a human Cc 1 region was amplified from a monocistronic pIgc1 vector 39 using primer pair Cg1_Fwd and Cg1_Rev (Table 2) , in which the 59-ends are complementary to the CSPG4 V H terminus and vector sequence downstream of Ce respectively, while the 39-ends are Cc 1 specific. The Cc 1 region PCR had an extension 35 , which stably expresses the human tetrameric (abc2) high-affinity IgE receptor (FceRI) was a kind gift from Prof. J-P. Kinet (Harvard University, Boston, MA) and was grown in DMEM supplemented with 10% FCS, 500 mg/mL Geneticin and 2 mM L-glutamine. Suspension serum-free adapted FreeStyle TM 293-F cells (R790-07, Life Technologies) 44 were cultured in FreeStyle TM 293 Expression Medium. All cell lines were supplemented with penicillin (5000 U/mL) and streptomycin (100 mg/mL) and maintained in a 5% CO 2 humidified incubator at 37uC.
Recombinant Antibody Production. Suspension and serum-free adapted FreeStyle ) and a dual antibody expression vector (pVITRO1-CSPG4-IgE/k), samples were collected every 48 h and IgE expression levels were determined by anti-human IgE ELISA as described previously 45 . Cultured supernatants were harvested after 16 days, centrifuged at 1000 3 g for 15 minutes, passed over 0.45 mm filters (Sartorius) and stored at 4uC with 0.1% sodium azide (Sigma) until use.
Purification of Recombinant Antibodies. Chimeric anti-CSPG4 IgG 1 and human 102.1F10 IgG 1-4 were purified by affinity chromatography with a 5 mL HiTrap Protein-G HP column (GE Healthcare) using an Ä KTA Prime system (GE Healthcare) and 0.2 mm filtered buffers. The column was equilibrated with 10 Column Volumes (CV) of phosphate buffered saline (PBS) washing buffer (pH 7.0) and the supernatant loaded at a flow rate of 2 mL/min, followed by 10 CV of washing buffer. The antibody was eluted with 0.2 M Glycine buffer (pH 2.3) and 2.5 mL fractions were collected into tubes containing 0.5 mL 1 M Tris-HCl pH 8.6 for neutralization.
Chimeric anti-CSPG4 IgE and human 102.1F10 IgE/IgA 1 /IgA 2 were purified by mixed-mode chromatography with a 5 mL pre-packed MEP HyperCel TM column (Pall Corporation) using an Ä KTA Prime system as described previously 46 . Briefly, the column was equilibrated with 10 CV of washing buffer (PBS, pH 7.0) and the supernatant loaded at a flow rate of 2 mL/min, followed by 20 CV washing buffer and 20 CV sterile water.
Step-elution with a series of 5 CV of 50 mM sodium acetate buffers with incrementally decreasing pH values (5.6-3.0) was used to elute the IgE antibodies at pH 5.2 and the IgA antibodies at pH 4.9. The column was cleaned with 1 M NaOH for 60 minutes and re-equilibrated with 20 CV washing buffer between runs.
SDS-Polyacrylamide Gel Electrophoresis. Purity and apparent molecular weight of purified antibodies was assessed by SDS-PAGE analysis. 1 mg of each antibody was subjected to a gradient 5-12% polyacrylamide gel under non-reducing and 5-20% gel under reducing conditions. For reduction, 10% b-mercaptoethanol was added to the denaturating sample buffer and all samples were incubated for 2 minutes at 90uC. Spectra TM Multicolor High Range Protein Ladder (Fermentas) or Protein Ladder (10-250 kDa) (New England Labs) were used to assess the approximate size of proteins visualized by Coomassie blue staining.
Size exclusion chromatography. Purified antibodies were analysed by size exclusion chromatography as previously described 33 . Briefly, gel filtration was performed on a Gilson HPLC system using a Superdex TM 200 10/300 GL column (GE Healthcare), suitable for purifying proteins between 10-300 kDa, at a flow rate of 0.75 mL/min in PBS (pH 7.0, 0.2 mm filtered). 35 expressing the human FceRI receptor. Cells were incubated with 0.4 mg/mL purified antibodies for 30 minutes at 4uC, followed by two washes in PBS supplemented with 5% normal goat serum (FACS buffer). Cells were then incubated with either 10 mg/ mL goat anti-human IgE-FITC (Vector Labs) or goat anti-human IgG-FITC (Jackson ImmunoResearch) for 30 minutes at 4uC and washed with FACS buffer prior to acquisition and analysis on a FACS Canto TM flow cytometer (BD Biosciences).
Immunofluoresence staining of cells grown on glass chamber slides. A375 melanoma cells (ATCC) were seeded in LabTek glass chamber slides (Nunc) at a density of 2 3 10 4 cells per well. Cells were washed in PBS and fixed in 4% formaldehyde PBS for 15 minutes and then incubated with PBS-T, 10% goat serum, 0.05% Tween for 25 minutes at room temperature. Anti-CSPG4 IgG 1 /IgE or control NIP antibodies were incubated for 45 minutes with A375 cells at a concentration of 10 mg/mL. Cell-bound antibodies were detected with a secondary goat anti-human IgG-FITC (Jackson ImmunoResearch) or goat anti-human IgE antibody conjugated to FITC (Vector Labs). Nuclei were stained in Hoechst dye for 3 minutes. All washing steps used PBS, except the final wash with dH 2 0. Cells were then mounted in Mowiol (Sigma) mounting medium. Fluorescence microscopy was performed on a Zeiss Axiovert Z.1 (403 objective) upright microscope. AxioCamMR3 and AxioVision Software (Carl Zeiss) was used for acquisition and analysis.
Phl p 7 specific anti-human ELISA. ELISA plates (Maxisorp, Nunc) were coated with 5 mg/mL of recombinant Phl p 7 (MRC/Asthma UK Protein Production Facility, King's College London, UK). Plates were blocked with PBS/1% BSA and washed throughout with PBS/0.05% Tween-20. 1 mg/mL purified 102.1F10 IgG 4 /IgE, negative isotype controls human myeloma IgG 4 (Calbiochem), MOv18 IgE 34 and positive control Phl p 7 reactive patient serum 12 were incubated in triplicate for 2 hours at room temperature, followed by incubation with isotype specific antibodies. IgG 4 antibodies were detected with mouse anti-human IgG 4 biotin-conjugated antibody (clone G17-4, BD Biosciences), incubated at 1 mg/mL, followed by streptavidin-horseradish peroxidase (R&D Systems). IgE antibodies were detected with polyclonal goat anti-human IgE (Sigma-Aldrich) directly conjugated with horseradish peroxidase using the manufacturer's recommended dilutions. ELISA plates were developed using TMB (R&D Systems) by measuring absorbance at 450 nm.
Ethics Statement. Human serum was obtained with written, informed consent and the London and City Research Ethics Committee approved the study.
